Transcatheter aortic valve implantation: role of multimodality cardiac imaging

Current evidence based on more than 8000 high-risk patients with severe aortic stenosis has demonstrated that transcatheter aortic valve implantation (TAVI) is a feasible alternative to surgical aortic valve replacement in selected patients. Despite current promising results on hemodynamic and clinical improvements, there are several unresolved safety issues, such as the frequency of vascular complications, postprocedural paravalvular leak, atrioventricular heart block and stroke. Multimodality cardiac imaging may help to minimize these complications and may play a central role before (optimizing patient selection, selection of appropriate prosthesis size and anticipating the procedural approach), during and after TAVI (evaluating the immediate and long-term procedural results). This article reviews the state-of-the-art TAVI procedures and the role that multimodality cardiac imaging plays before, during and after TAVI.     

Transcatheter aortic valve implantation: technique,complications and perspectives

Transcatheter aortic valve implantation (TAVI) has become the preferred treatment option for patients with symptomatic severe aortic stenosis who are inoperable or at high risk for surgical aortic valve replacement. TAVI has shown a clear mortality benefit compared to conservative treatment in inoperable patients, and is at least non-inferior to surgical aortic valve replacement in high-risk operable patients. Through improvements in the field of imaging, refinement in valve technologies, increasing operator and team experience and continuous valuable research, TAVI has developed rapidly in the past years and is expected to further boost in the near future. In this review, we discuss the technical and procedural aspects of TAVI, the acute and late outcomes, and highlight the current expectations and potential future development of this rapidly evolving technology.     

Renal dysfunction and transcatheter aortic valve implantation outcomes

Introduction: Transcatheter aortic valve implantation (TAVI) underwent progressive improvements until it became the default therapy for inoperable patients, and a recommended therapy in high-risk operable patients with symptomatic severe aortic stenosis. Recent evidence will further support TAVI as treatment for a growing number of patients.

Areas covered: This review will discuss on the current knowledge about the role of both pre-procedural chronic kidney disease (CKD) and post-procedural acute kidney injury (AKI) in adult patients with severe aortic stenosis undergoing TAVI.

Expert commentary: Pre-procedural CKD is one of the most frequent comorbidities of TAVI patients and has been found to significantly worsen patients’ prognosis at short and long-term follow-up. Similarly, post-procedural AKI is a frequent and relevant complication associated with increased mortality. The risk stratification of the patient, the prevention of complications and the appropriate post-procedural management are the main focus of the future research aimed at further improving clinical outcomes of TAVI patients.     

Transcatheter CoreValve valve‐in‐valve implantation in a stentless porcine aortic valve for severe aortic regurgitation

We describe the first valve‐in‐valve Corevalve transcatheter aortic valve replacement in the St. Jude Toronto stentless porcine aortic valve in the United States, which enabled this 59‐year‐old patient with a history of bacterial endocarditis and aortic regurgitation to avoid heart transplant with complete resolution of his severe left ventricular dysfunction.     

Transcatheter valve repair/implantation

Real time 3-dimensional transesophageal echo is a relatively new technology that enables online imaging that is highly accurate and precise for evaluating cardiac structures. Moreover, this methodology allows for accurate online guidance of interventional cardiac procedures for structural heart disease. In this report, we describe the use of real time, 3D transesophageal (TEE) for aortic valve replacement with percutaneous, bioprosthetic valves as well as for transcatheter mitral repair with the MitraClip device. For each procedure, we describe 3D evaluation of valvular structures prior to the procedure, and how 3D imaging is used to guide the procedure as well as to assess the results of the procedure. Use of 3D TEE has proven to be a substantial advance for evaluating patients prior to percutaneous heart valve procedures and especially for guiding and monitoring percutaneous, transcatheter heart valve procedures.     

Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV

We report a case of a 54-year-old patient who was denied surgical replacement for severe aortic stenosis because of complicated acquired immunodeficiency syndrome and who successfully underwent transcatheter aortic valve implantation at our institution.     

Transcatheter Edwards Sapien XT valve in valve implantation in degenerated aortic bioprostheses via transfemoral access

Objectives

Surgical treatment of degenerated aortic bioprostheses is associated with an increased risk of morbidity and mortality, especially in elderly patients with significant co-morbidities. Therefore, transcatheter aortic valve implantation (TAVI) performed as valve in valve technique appears as an attractive alternative treatment option. We report of a case series of seven patients with dysfunctional bioprosthetic aortic heart valves who have been treated with TAVI via transfemoral access.

Methods and results

Valve in valve implantation using the Edwards Sapien XT bioprostheses (Edwards Lifesciences LLC, Irvine, CA, USA) was performed in eight patients (3 men, 5 women, mean age 85.3?±?6.1?years) with a high operative risk (logistic euroSCORE 27.2?±?7.3). Six patients underwent TAVI because of high grade stenosis of the aortic bioprostheses, whereas two patients presented with high grade regurgitation. All patients suffered at least from NYHA class III dyspnea during admission. TAVI was successfully performed via transfemoral access under local anesthesia with mild analgesic medication in all cases. Mild aortic regurgitation occurred in three patients while no permanent pacemaker implantation was required. Major cardiac events or cerebrovascular events did not occur. One aneurysm spurium, with the need of one blood transfusion, occurred. All patients improved at least one NYHA class within 30?days.

Conclusion

TAVI for degenerated aortic bioprostheses, using the Edwards Sapien XT valve via transfemoral access is a feasible option for patients at high surgical risk.     

Transcatheter treatment approaches for aortic valve disease

Transcatheter aortic valve implantation (TAVI) for the management of symptomatic aortic stenosis has evolved rapidly over the last ten years, to the point where TAVI has recently been established as the standard of care for inoperable patients. With the results of further trials, steady improvements in device design and a greater understanding, it is anticipated that the indications for TAVI will expand to include patients at high risk of complications from surgical aortic valve replacement. As we see the widespread implementation of TAVI programs worldwide, it is timely for a review on the current status of percutaneous transarterial implantation of the aortic valve.     

Modular aortic valve prosthesis for transcatheter aortic valve implantation: a novel concept with a new implantation method

Transcatheter aortic valve implantation (TAVI) is a relatively new medical intervention. Research on dedicated TAVI devices is an exciting and dynamic field to be explored by professionals involved in technological innovation. The authors describe in this article the first engineering concept and part of the US Patent of a new valve prosthesis. Divided into two pieces to be separately implanted using a single catheter by means of an innovative technique, this device aims at reducing prosthesis and delivery catheter profile. Miniaturization of the valve and delivery system is probably the best solution to reduce the morbidity and mortality that derive from vascular complications associated with TAVI.     

Aortic valve prosthesis tracking for transapical aortic valve implantation

Purpose  

Transapical aortic valve implantation (TA-AVI) is a new minimally invasive surgical treatment of aortic stenosis for high-risk patients. The placement of aortic valve prosthesis (AVP) is performed under 2D X-ray fluoroscopic guidance. Difficult clinical complications can arise if the implanted valve is misplaced. Therefore, we present a method to track the AVP in 2D X-ray fluoroscopic images in order to improve the accuracy of the TA-AVI.     

Transcatheter aortic valve implantation in patients with severely reduced left ventricular systolic function: a single-center experience

Aims

Current guidelines consider severe systolic left ventricular dysfunction [ejection fraction (EF) ≤20 %; left ventricular dysfunction (LVD)] a contraindication for transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the efficacy and safety of TAVI in this extreme risk subset of patients.

Methods and Results

The study population (253 patients) was divided into two groups; the LVD group [21 patients with left ventricular ejection fraction (LVEF) ≤20 %] and the control group (232 patients with LVEF >20 %). TAVI was generally performed transfemorally under analgosedation without mechanical circulatory support. Clinical and hemodynamic variables, as well as procedural and follow-up outcomes, were compared, and all events were defined according to the Valve Academic Research Consortium criteria for event definition. Mean EF in the LVD group was 18.3 ± 2.9 % compared to 50.9 ± 11.3 % in the control group. Patients in the LVD group were younger, more commonly males, had higher logistic EuroSCORE and lower mean aortic pressure gradients. Immediate procedural mortality was low and similar in both groups (0 vs. 2.2 % in the LVD and control group, respectively, p = 0.49). At 30 days, post-procedural vascular and bleeding complications as well as strokes were similar, but all-cause mortality was higher in the LVD group (14.3 vs. 3.4 %, p = 0.05). In the survivors of the LVD group, New York Heart Association functional class and LVEF significantly improved at 30 days and 6 months. Survival at 1 and 2 years was 70.2 vs. 86.0 % and 56.1 vs. 78.3 % in the LVD and control group, respectively (log-rank p = 0.03).

Conclusions

TAVI without mechanical circulatory support appears feasible, safe and effective in patients with severe aortic stenosis and severe LVD, but short- and long-term mortality remain high. TAVI should be considered a viable treatment option in this subset of extremely compromised patients.     

Transcatheter aortic valve replacement: the changing paradigm of aortic stenosis treatment

Aortic stenosis is the most common cause for valvular surgery in the USA. For nearly 50 years, surgical aortic valve replacement has been the standard of care for symptomatic patients; unfortunately, a significant number of patients are not referred to surgery owing to advanced comorbidities and age. Transcatheter aortic valve replacement has emerged as an effective therapy for patients at high risk for surgery. Through device innovations and accumulated experience, the safety and efficacy of the procedure has improved since its inception. Transcatheter valve replacement has been found superior to medical therapy in inoperable patients with aortic stenosis, yet many questions remain as to which patients are appropriate for this exciting and novel therapy.     

Transcatheter aortic valve replacement and cardiac conduction

Introduction: Conduction abnormalities after transcatheter aortic valve replacement (TAVR) account for a high percentage of post-TAVR complications.

Areas covered: The etiology of conduction abnormalities is closely tied to cardiac anatomy (length of membranous septum, degree of calcification, location of left bundle within the membranous septum), baseline conduction abnormalities (preprocedure right bundle branch block), and procedural variables (type of valve, depth of implant). Management of new high-grade AV block and new left bundle branch block varies by institution in the absence of consensus guidelines.

Expert opinion: Authors describe the incidence, etiology, outcomes, and management of conduction abnormalities related to aortic stenosis and TAVR.     

Transcatheter aortic valve replacement: the changing paradigm of aortic stenosis treatment

Aortic stenosis is the most common cause for valvular surgery in the USA. For nearly 50 years, surgical aortic valve replacement has been the standard of care for symptomatic patients; unfortunately, a significant number of patients are not referred to surgery owing to advanced comorbidities and age. Transcatheter aortic valve replacement has emerged as an effective therapy for patients at high risk for surgery. Through device innovations and accumulated experience, the safety and efficacy of the procedure has improved since its inception. Transcatheter valve replacement has been found superior to medical therapy in inoperable patients with aortic stenosis, yet many questions remain as to which patients are appropriate for this exciting and novel therapy.     

Adjuncts to transcatheter aortic valve implantation

Introduction: The appreciable rise in percutaneous valve procedures has been pursued by a wave of development in advanced technology to help guide straightforward, streamlined and safe intervention. This review article aims to highlight the adjunctive devices, tools and techniques currently used in transcatheter aortic valve implantation procedures to avoid potential pitfalls.

Areas covered: The software and devices featured here are at the forefront of technological advances, most of which are not yet in widespread use. These products have been discussed in national and international structural intervention conferences and the authors felt it important to showcase particularly well designed adjuncts that improve procedural efficacy and safety. Whilst vascular pre-closure systems are used routinely and are an integral part of these complex cardiovascular procedures, these have been well summarised elsewhere and are beyond the scope of this article.

Expert commentary: The rising volume of patients with aortic stenosis who are treatable with TAVI means that this exponential increase in procedures must be accompanied by a steady decline in procedural complications. This section provides an overview of our current perspective, and what we feel the direction of travel will be.     

经导管主动脉瓣植入术前的综合影像学评估

退行性病变是老年人心脏瓣膜病主要的原因,其中主动脉瓣钙化致主动脉瓣狭窄为最常见的心脏瓣膜病之一.有临床症状的主动脉瓣重度狭窄患者预后极差,每年的死亡率约25％[1].传统的外科主动脉瓣置换术是其治疗的金标准,但超过30％的患者却没有手术机会[2].一种新兴的治疗方式——经导管主动脉瓣植入术( transcatheter aortic valve implantation,TAVI)正在不断的发展,截至目前,全球超过35 000例患者接受这种治疗,成功率达93％～98％[3].然而,要达到成功施行TAVI同时使并发症最少,准确选择适合的患者是非常重要的,这需要术前多种影像学方法准确的评估.本文就TAVI术前的综合影像学评估综述如下.     

Local versus general anesthesia for transfemoral aortic valve implantation

Background

Transcatheter aortic valve implantation (TAVI) represents a novel option for elderly with severe aortic valve stenosis who are denied surgical aortic valve replacement due to high perioperative risk. While transfemoral TAVI generally is being performed in general anesthesia (GA), TAVI under local anesthesia plus mild sedation (LAPS) might be an effective and safe alternative.

Methods

In a single-centre analysis, we assessed clinical data, preoperative risk scores (STS-Score), echocardiography, periprocedural data and labor costs in 74 patients undergoing transfemoral TAVI under GA (n?=?33) and LAPS (n?=?41).

Results

Patients who underwent TAVI in LAPS presented significantly more often with pulmonary hypertension and impaired renal function, and tended to have a higher STS score and more severe symptoms (higher NYHA class) versus the GA group. There were no significant differences in procedure-related 30-day mortality or complications between groups. The peak systolic and mean central aortic pressure were significantly higher in the LAPS group, while at the same time these patients required significantly less often periprocedural adrenergic support. Intervention time was shorter in the LAPS group due to avoidance of surgical cut-down of the access site. Moreover, total procedure time was significantly shorter and labor costs were lower in the LAPS group. Patients who underwent TAVI in LAPS could be mobilized significantly earlier.

Conclusion

Our study indicates that TAVI under LAPS is as effective and safe as TAVI under GA. Furthermore, total procedure time, intervention time and labor costs could be reduced by LAPS. Mobilization of patients could be achieved earlier. We therefore consider LAPS to be favorable in patients undergoing transfemoral TAVI.